nCounter® Autoimmune Profiling Panel
Helping Your Research
Get insights into immune system dysfunction quickly with our comprehensive 770 gene multiplex panel for human or mouse to evaluate the pathways, processes, and cell types involved in autoimmune disease, chronic inflammatory disease, and immunotherapy-related adverse events. Analyze autoimmune biomarkers rapidly without the need for qPCR or NGS.
- Therapeutic mechanism of action (MOA) studies
- Immunotherapy-induced adverse event investigations
- Discovery/validation of disease and therapeutic specific biomarkers
- Development of predictive signatures of drug response
- Compatible with challenging sample types such as PBMCs and FFPE
How it Works
The nCounter Autoimmune Profiling panels are designed to rapidly characterize the biology behind autoimmune disease and an aberrant immune response. Each human and mouse panel allow for a comprehensive evaluation of pathways, processes, and cell types that are involved in autoimmune disease and chronic inflammatory disorders.
Comprehensive assessment of 35 pathways and processes associated with autoimmune disease and chronic inflammatory disorders
Unique cell typing analysis feature measures the relative abundance of 14 different immune cell types
Customizable with Panel Plus option – add up to 55 genes of your choice
Streamlined workflow with just 15 minutes total hands-on time
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel proFind Your Panel
The TruCulture-NanoString Solution for Immune Profiling
Recent publications (1,2) from the Milieu Interieur project at Institut Pasteur have shown the utility of the Myriad RBM TruCulture(1) whole blood collection and culture system paired with nCounter gene expression analysis.
For more information on the combined TruCulture-NanoString workflow, visit the Myriad TruCulture site.
In the Lab
The 35 pathways and processes in this panel provide a comprehensive view into immune system dysfunction in autoimmune disease and treatment-induced adverse immune events.
The Autoimmune Profiling Panels include unique cell profiling signatures to measure the relative abundance of 14 different immune cell types1. The table below summarizes each cell type represented by gene content in the panel, as qualified through biostatistical approaches and selected literature in the field of immunology.
The Autoimmune Profiling Panel is designed to encompass adaptive and innate immune system dysfunction associated with six of the most common and debilitating autoimmune diseases. The table below describes the six conditions that were emphasized in creating this panel, along with induced adverse immune events associated with immunotherapy. While this panel was designed around these six diseases, it will provide powerful immune system information for the research of any autoimmune or chronic inflammatory disorder.
Content in the Autoimmune Profiling Panel includes targets for more than 30 approved and investigational therapies for autoimmune disease and chronic inflammatory disorders.
Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation.
PURPOSE: Patients with heterozygous gain-of-function (GOF) mutations in STAT1 frequently exhibit chronic mucocutaneous candidiasis (CMC), immunodeficiency and autoimmune manifestations. Several treatment options including targeted therapies and hematopoietic stem cell transplantation (HSCT) are available for STAT1 GOF patients but modalities and outcomes are not well established.
The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus.
Objectives: Type I interferons (IFNs) play an important role in the pathophysiology of systemic lupus erythematosus (SLE). While cross-sectional data suggest an association between IFN-induced gene expression and SLE disease activity, interest in this as a biomarker of flare has been tempered by a lack of fluctuation with disease activity in the majority of patients.
The Role of Brain-Derived Neurotrophic Factor in Irritable Bowel Syndrome.
Several studies have implied a role of brain-derived neurotrophic factor (BDNF) in abdominal pain modulation in irritable bowel syndrome (IBS). The aim of this study was to establish BDNF protein expression in human colonic biopsies and to show variation in IBS compared to controls.